- Home
- ITRG vs DMAC Comparison
ITRG vs DMAC Comparison
Compare ITRG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRG
- DMAC
- Stock Information
- Founded
- ITRG 1997
- DMAC 2000
- Country
- ITRG Canada
- DMAC United States
- Employees
- ITRG N/A
- DMAC N/A
- Industry
- ITRG Precious Metals
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ITRG Basic Materials
- DMAC Health Care
- Exchange
- ITRG Nasdaq
- DMAC Nasdaq
- Market Cap
- ITRG 302.5M
- DMAC 310.1M
- IPO Year
- ITRG N/A
- DMAC N/A
- Fundamental
- Price
- ITRG $2.56
- DMAC $6.14
- Analyst Decision
- ITRG Strong Buy
- DMAC Strong Buy
- Analyst Count
- ITRG 2
- DMAC 3
- Target Price
- ITRG $3.25
- DMAC $12.33
- AVG Volume (30 Days)
- ITRG 2.0M
- DMAC 345.3K
- Earning Date
- ITRG 08-13-2025
- DMAC 08-12-2025
- Dividend Yield
- ITRG N/A
- DMAC N/A
- EPS Growth
- ITRG N/A
- DMAC N/A
- EPS
- ITRG 0.09
- DMAC N/A
- Revenue
- ITRG $148,447,000.00
- DMAC N/A
- Revenue This Year
- ITRG $871.24
- DMAC N/A
- Revenue Next Year
- ITRG N/A
- DMAC N/A
- P/E Ratio
- ITRG $30.13
- DMAC N/A
- Revenue Growth
- ITRG N/A
- DMAC N/A
- 52 Week Low
- ITRG $0.79
- DMAC $3.19
- 52 Week High
- ITRG $2.57
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- ITRG 83.18
- DMAC 63.38
- Support Level
- ITRG $2.34
- DMAC $5.14
- Resistance Level
- ITRG $2.55
- DMAC $6.16
- Average True Range (ATR)
- ITRG 0.12
- DMAC 0.34
- MACD
- ITRG 0.05
- DMAC -0.07
- Stochastic Oscillator
- ITRG 98.05
- DMAC 94.34
About ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.